News & Updates

Patients with inflammatory bowel disease (IBD) who use statins appear to have a substantially reduced risk of primary sclerosing cholangitis (PSC), as shown in a retrospective study.

The intermittent 48-h “gap” schedule of olaparib in combination with carboplatin/paclitaxel and anthracycline chemotherapy provides substantial survival benefits in patients with germline BRCA-mutated breast cancer (gBRCA) regardless of their pathological complete response (pCR) status, results of the PARTNER trial have shown.